Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A monoclonal antibody Covid treatment from Vir Biotechnology and GlaxoSmithKline “stands up well” to all variants of the virus, Vir President and CEO George Scangos told CNBC's “Power Lunch” on Wednesday.

CEO of Covid antibody maker Vir Biotech says their treatment 'stands up well' to all variants

GlaxoSmithKline

Britain's GlaxoSmithKline plc (LON: GSK) announced in a joint statement with the U.S. based Vir Biotechnology Inc (NASDAQ: VIR) on Wednesday that the U.S. government had agreed to buy about $1.0 billion worth of its antibody-based COVID-19 treatment. U.S. wants GSK to deliver the doses by December 17th   The number of doses of Sotrovimab […] The post U.S. places a sizable order for GSK-Vir's COVID-19 treatment appeared first on Invezz.

U.S. places a sizable order for GSK-Vir's COVID-19 treatment

The United States government has signed contracts worth about $1 billion to secure the antibody-based COVID-19 treatment developed by GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR). GSK said the deal brought the total number of doses secured for the treatment, sotrovimab, to more than 750,000 globally.

US Government Agrees To Purchase GSK-Vir Biotech's COVID-19 Antibody Doses Worth $1B

– US government contracts for approximately $1 billion1 (USD) now in place to purchase sotrovimab, further expanding access nationwide –

GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment

The U.S. government has agreed to buy more doses of an antibody drug for the early treatment of Covid-19 developed by GlaxoSmithKline and Vir Biotechnology bringing its total order to nearly $1 billion for a treatment found to reduce the risk of hospitalization.

The Wall Street Journal: U.S. government will buy more of GlaxoSmithKline and Vir's COVID antibody drug

Glaxo (GSK) and Vir announce non-inferiority of intramuscular administration of sotrovimab compared to intravenous administration in reducing hospitalization or death as an early treatment of mild-to-moderate COVID-19.

Glaxo (GSK), Vir Intramuscular Sotrovimab Meets Study Endpoint

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered via Intramuscular (IM) administration compared to IV administration in high-risk COVID-19 patients. The trial achieved its primary endpoint, demonstrating that IM administration of sotrovimab was non-inferior to intravenous (IV) administration for the early treatment of mild-to-moderate COVID-19 up to seven days after symptom onset.

GSK, Vir's Intramuscularly-Administered Sotrovimab Shows Efficacy At Par With IV Route In COVID-19

– New data from ongoing trials evaluating Vir's two novel HBV therapies continue to demonstrate  notable reductions in HBsAg and support their positive safety profiles –

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®

– COMET-TAIL Phase 3 data demonstrated that intramuscular administration of sotrovimab was  non-inferior and offered similar efficacy to intravenous administration for high-risk populations –

Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19

Efficacy results for oral antivirals from Pfizer and Merck are weighing heavily on Vir today.

Why Vir Biotechnology Stock Is Sliding Today

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 373.33% and 31.49%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) Beats Q3 Earnings and Revenue Estimates

– To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide –

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021.

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021

SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place virtually from November 12-15, 2021.

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD's The Liver Meeting® 2021

SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference on Wednesday, Oct. 13, at 9:30 a.m. PT / 12:30 p.m. ET.

Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) fell by over 21% in the previous trading session. This is why it happened.

VIR Stock Price: Why It Fell Over 21%

SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference on Wednesday, Oct. 6, at 11:30 a.m. PT / 2:30 p.m. ET.

Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference

Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19 antibody therapy. Related Link:   GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients.

Glaxo - Vir Biotech's COVID Treatment Approved In Japan

Shares fell after an analyst's downgrade.

Why Vir Biotechnology Stock Is Sinking This Week

Vicki Sato, Director at Vir Biotechnology (NASDAQ:VIR), made a large insider sell on September 17, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Sato sold 15,174 shares of Vir Biotechnology at prices ranging from $52.31 to $53.06.

Director Of Vir Biotechnology Sold $796.30 Thousand In Stock

Apple

Caterpillar

Salesforce

DigitalOcean Holdings

Goldman Sachs

Intel

Johnson & Johnson

JPMorgan Chase & Co

Travelers

UnitedHealth Group

Two new Breakout Stocks for Week 37 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +57.6% YTD with a record-high 21 out of 36 weeks this year in negative conditions above the 40 MG level.

Week 37 MDA Breakout Stocks - September 2021: Short-Term Picks To Give You An Edge

SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, Sept. 14 at 9:30 a.m. PT / 12:30 p.m. ET.

Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, Sept. 13, at 4:00 a.m. PT / 7:00 a.m. ET.

Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Regeneron Pharmaceuticals

Their products are seeing a surge in demand.

News for Vir Biotechnology Stock (VIR)